NewsRoom Articles - Page 24 of 208

WednesdaySep 04, 2024 9:45 am

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

The company is leveraging its extensive network of local partnerships to bring healthcare services directly into communities it serves Astiva is expanding network of activity centers, which are designed to be more than just places for medical care Astiva Health recognizes that true wellness goes beyond treating illness; it requires a proactive approach to health One of the pillars of Astiva Health’s approach to care is cultural responsiveness As the landscape of healthcare continues to shift toward more community-focused and personalized care, Astiva Health is launching a comprehensive community outreach initiative aimed at improving wellness and healthcare access for seniors across Southern…

FridayAug 30, 2024 10:00 am

Yale Study Unravels Autism, Brain Growth Patterns

Autism spectrum disorder, commonly referred to as autism, is a neurodevelopmental disorder that affects how a person interacts with others, as well as how they learn, communicate and behave. This disorder’s symptoms usually appear in the first two years of an infant’s life and often present as repetitive behaviors and restricted interests. A new study led by researchers at Yale has found a pair of neurodevelopmental abnormalities that may be associated with autism, with their differences being influenced by brain size. The researchers determined that these abnormalities arose just weeks after the brain started developing. For their study, the researchers…

ThursdayAug 29, 2024 10:30 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will…

WednesdayAug 28, 2024 10:00 am

Proposed US Law Would Direct Opioid Settlement Cash to Opioid Crisis Management

The opioid epidemic has seen millions lose their lives in the last 30 or so years. It began with prescription opioids and grew with heroin consumption, with the use of synthetic opioids such as fentanyl only making the situation worse. At the start of the year, Representatives Ashley Hinson and Marcy Kaptur introduced a measure that directs states to use settlement funds from pharmaceutical companies to address issues associated with opioids, such as prevention and treatment services. Allocating these funds to prevention and treatment services, including rehabilitation centers and opioid treatment programs, may help fight this crisis. These treatment programs…

WednesdayAug 28, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients In MS, CNM-Au8 can work in conjunction with…

TuesdayAug 27, 2024 10:00 am

AI Firms Gain Foothold in e-Commerce, Software, Healthcare Industries

Artificial intelligence (AI) seems to be making a mark on different industries, with some companies even recording growth in the healthcare and retail sectors. These companies are using artificial intelligence to address issues in these sectors, from rising medical bills to sizing issues in e-commerce. This indicates a possible shift in how industries are approaching different problems. One provider of AI-driven measurement solutions for e-commerce, MySize Inc., announced strong results from its second quarter. The company recorded a 53% increase in its revenues, driven primarily by its sizing tech and e-commerce platform powered by artificial intelligence. It also saw its…

MondayAug 26, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

The company has released key corporate and business updates and Q2 2024 financial results Clinical trials for both Alzheimer’s and Parkinson’s studies yielded encouraging data for lead compound buntanetap Buntanetap in combination with GLP-1 agonist dulaglutide Trulicity(R) showed increased potential to synergistically enhance cognition The company has obtained a patent and begun manufacturing of a new crystalline form of buntanetap, with improved properties Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

FridayAug 23, 2024 10:00 am

How Health Technology Could Improve Customer Experience

Any business in the healthcare sector seeking to improve customer experience, popularly known as CX, may benefit from using health technology. Data from Forrester Research shows that 6% of brands that took part in the 2023 U.S. Customer Experience rankings saw increases in quality of customer experiences. 8x8’s chief technology officer, Bryan Martin, believes this may be because brands aren’t investing in processes and tools to enhance customer experiences. To boost customer experiences, healthcare organizations can concentrate on: Automation and Artificial Intelligence The use of manual processes is frustrating, not only for organizations but also to patients. Automation of an…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

Yale Study Unravels Autism, Brain Growth Patterns

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

Proposed US Law Would Direct Opioid Settlement Cash to Opioid Crisis Management

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

AI Firms Gain Foothold in e-Commerce, Software, Healthcare Industries

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

How Health Technology Could Improve Customer Experience

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search